Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionVoya Investment Management Llc
Latest Disclosed Ownership196,541 shares
Latest Disclosed Value $ 5,839,233
Voya Investment Management Llc reports 26.07% increase in ownership of TVTX / Travere Therapeutics, Inc.

On May 12, 2026 - Voya Investment Management Llc filed a 13F-HR form disclosing ownership of 196,541 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $5,839,233 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 155,895 shares of Travere Therapeutics, Inc.. This represents a change in shares of 26.07% during the quarter. The current value of the position is $8,883,653 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 196,541 40,646 26.07 5,839 -1.96 0.0050
2026-02-12 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 155,895 -38,959 -19.99 5,957 27.89 0.0059
2025-10-09 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 194,854 27,133 16.18 4,657 87.63 0.0046
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 167,721 44,812 36.46 2,482 12.72 0.0025
2025-06-18 2025-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 122,909 -76,763 -38.44 2,203 -36.69 0.0013
2025-06-18 2025-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 122,909 2,203
2025-06-18 2025-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 122,909 2,203
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 122,909 -76,763 2,203 0.0012
2025-05-02 2024-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 199,672 -22,798 -10.25 3,478 11.76 0.0036
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 199,672 -22,798 3,478 0.0018
2025-02-07 2024-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 222,470 197,528 791.95 3,112 1,418.05 0.0032
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 222,470 197,528 3,112 0.0032
2025-02-07 2024-06-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 24,942 -182,840 -88.00 205 -87.20 0.0002
2024-12-03 2024-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 24,942 -182,840 205 0.0002
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 24,942 -182,840 205 0.0002
2025-02-07 2024-03-31 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 207,782 178,402 607.22 1,602 506.82 0.0016
2024-12-06 2024-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 207,782 178,402 1,602 0.0016
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 207,782 178,402 1,602 0.0018
2025-02-07 2023-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 29,380 -18,595 -38.76 264 -38.32 0.0003
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 29,380 -18,595 264 0.0003
2025-02-07 2023-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 47,975 569 1.20 429 -41.21 0.0005
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 47,975 569 429 0.0006
2025-02-07 2023-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 47,406 5,389 12.83 728 -22.88 0.0008
2023-08-14 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 47,406 5,389 728 0.0009
2025-02-07 2023-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 42,017 0 0.00 945 6.91 0.0010
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 42,017 0 945 0.0012
2025-02-07 2022-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 42,017 -1,330 -3.07 884 -17.32 0.0010
2023-02-14 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 42,017 -1,330 884 0.0004
2025-02-07 2022-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 43,347 -45,635 -51.29 1,068 -50.44 0.0013
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 43,347 -45,635 1,068 0.0011
2022-08-15 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 88,982 65,560 279.91 2,155 256.79 0.0054
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 23,422 409 1.78 604 -15.52 0.0013
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 23,013 -291 -1.25 715 26.55 0.0014
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 23,304 -20 -0.09 565 65.69 0.0011
2021-08-16 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 23,324 317 1.38 341 -40.59 0.0007
2021-05-17 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 23,007 977 4.43 574 -4.33 0.0012
2021-02-16 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 22,030 6,620 42.96 600 111.27 0.0012
2020-11-16 2020-09-30 13F RETROPHIN COM 761299106 15,410 688 4.67 284 -5.33 0.0006
2020-08-14 2020-06-30 13F RETROPHIN COM 761299106 14,722 -5,853 -28.45 300 0.00 0.0007
2020-05-15 2020-03-31 13F RETROPHIN COM 761299106 20,575 0 0.00 300 2.74 0.0008
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 20,575 2,725 15.27 292 41.06 0.0006
2019-11-26 2019-09-30 13F/A-1 RETROPHIN COM 761299106 17,850 0 0.00 207 -42.34 0.0005
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 17,850 0 207 219.0827
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 17,850 734 4.29 359 -7.24 0.0008
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 17,116 0 0.00 387 0.00 0.0009
2019-02-14 2018-12-31 13F RETROPHIN COM 761299106 17,116 1,073 6.69 387 -16.05 0.0010
2018-11-14 2018-09-30 13F RETROPHIN COM 761299106 16,043 0 0.00 461 5.49 0.0009
2018-08-14 2018-06-30 13F RETROPHIN COM 761299106 16,043 -1,862 -10.40 437 9.25 0.0009
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 17,905 0 0.00 400 6.10 0.0009
2018-02-14 2017-12-31 13F RETROPHIN COM 761299106 17,905 0 0.00 377 -15.47 0.0008
2017-11-14 2017-09-30 13F RETROPHIN COM 761299106 17,905 0 0.00 446 28.53 0.0010
2017-08-14 2017-06-30 13F RETROPHIN COM 761299106 17,905 1,891 11.81 347 17.23 0.0008
2017-05-15 2017-03-31 13F RETROPHIN COM 761299106 16,014 0 0.00 296 -2.31 0.0007
2017-02-14 2016-12-31 13F RETROPHIN COM 761299106 16,014 0 0.00 303 -15.36 0.0007
2016-11-14 2016-09-30 13F RETROPHIN COM 761299106 16,014 0 0.00 358 25.61 0.0007
2016-08-15 2016-06-30 13F RETROPHIN COM 761299106 16,014 1,148 7.72 285 40.39 0.0007
2016-05-16 2016-03-31 13F RETROPHIN COM 761299106 14,866 0 0.00 203 -29.27 0.0005
2016-02-12 2015-12-31 13F RETROPHIN COM 761299106 14,866 0 0.00 287 -4.65 0.0007
2015-11-16 2015-09-30 13F RETROPHIN COM 761299106 14,866 -2,373 -13.77 301 -47.29 0.0008
2015-08-14 2015-06-30 13F RETROPHIN COM 761299106 17,239 1,947 12.73 571 56.01 0.0013
2015-05-15 2015-03-31 13F RETROPHIN COM 761299106 15,292 0 0.00 366 95.72 0.0008
2015-02-10 2014-12-31 13F RETROPHIN COM 761299106 15,292 0 0.00 187 35.51 0.0004
2014-11-12 2014-09-30 13F RETROPHIN COM 761299106 15,292 0 0.00 138 -23.33 0.0003
2014-08-13 2014-06-30 13F RETROPHIN COM 761299106 15,292 15,292 180 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.